CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Athenex Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Athenex Inc
1001 Main St Ste 600
Phone: (716) 898-8625p:716 898-8625 BUFFALO, NY  14203-1009  United States Fax: (716) 800-6816f:716 800-6816
This company's Plan of Liquidation went into effect on 9/22/2023
This company is no longer actively traded on any major stock exchange.
Business Summary
Athenex, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of next-generation products for the treatment of cancer. The Company's segments include Oncology Innovation Platform and Commercial Platform. The Oncology Innovation Platform is engaged in research and development of its drugs. The Commercial Platform is focused on the sales and marketing of its specialty drugs and the market development of its drugs. Its clinical pipeline in the Oncology Innovation Platform is derived from its technologies: Cell Therapy, based on natural killer T (NKT) cells, and Orascovery, based on a P-glycoprotein pump inhibitor. Its product candidates include KUR-501, KUR-502, and KUR-503. KUR-501 is an autologous product in which NKT cells are engineered with a chimeric antigen receptor (CAR) targeting disialoganglioside (GD2). KUR-503 is an allogeneic product in which NKT cells are engineered with a CAR targeting glypican-3.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-YesYesYes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202212/31/2022YesYesYes-Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board and Chief Executive Officer Johnson Y.Lau 62 1/1/2011 11/1/2003
Chief Restructuring Officer NickCampbell 4/19/2023 4/19/2023
Chief Business and Commercial Officer - Proprietary Drugs TimothyCook 61 12/22/2021 12/22/2021
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
ATHENEX EURO LIMITED NEW PENDEREL HOUSE 4TH FLOOR 283 - 288 HIGH HOLBORN United Kingdom
Cell Medica GmbH Friedrichstrae 100 Berlin Germany
ATHENEX BELGIUM BV KEMPISCHE STEENWEG 305 HASSELT Belgium
5 additional Subsidiary records available in full report.

Business Names
Business Name
Athenex API Limited
Athenex Belgium
Athenex Biomedical International Holdings Limited
39 additional Business Names available in full report.

General Information
Number of Employees: 269 (As of 12/31/2022)
Outstanding Shares: 8,663,209 (As of 3/13/2023)
Shareholders: 121
Stock Exchange: OTC
Federal Tax Id: 431985966
Fax Number: (716) 800-6816


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 17, 2024